Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41–BEVANEC randomized phase II study
Titel:
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41–BEVANEC randomized phase II study
Auteur:
Walter, Thomas Malka, David Hentic, Olivia Lombard-Bohas, Catherine Le Malicot, Karine Smith, Denis Ferru, Aurélie Assenat, Eric Cadiot, Guillaume Lievre, Astrid Kurtz, Jean-Emmanuel Dahan, Laetitia Dubreuil, Olivier Hautefeuille, Vincent Lepere, Céline Gangloff, Alice Elhajbi, Farid Coriat, Romain Roquin, Guillaume Bouarioua, Nadia Granger, Victoire Scoazec, Jean-Yves Lepage, Côme